Kenneth Maverick, MD
Ophthalmology · San Antonio, TXNPI 1720132962
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Rxsight Inc accounts for 63.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $20,089 and has fallen 93.1% since, to $1,393 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $235.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$21K
- Lensar, Inc.$8K
- Glaukos Corporation$890
- AbbVie$444
- Biotissue Holdings Inc.$422
- Johnson & Johnson Surgical Vision, Inc.$357
- plus $2K from 20 others
Across 185 payments — averaging $2566.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$355K
- Johnson & Johnson Surgical Vision, Inc.$110K
- Glaukos Corporation$9K
What the payments were for
- Consulting fees$19,36660%
- Speaking & faculty fees$7,52623%
- Food & beverage$5,30416%
- Gifts$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 19 | $20,543 |
| Lensar, Inc. | 13 | $7,891 |
| Glaukos Corporation | 10 | $890 |
| AbbVie(2 entities) | 19 | $444 |
| Biotissue Holdings Inc. | 9 | $422 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $357 |
| Amgen | 2 | $276 |
| Novartis | 7 | $272 |
| NEW World Medical,inc. | 6 | $193 |
| Alcon | 10 | $183 |
| Ocular Therapeutix, Inc. | 5 | $106 |
| Nova Eye, Inc. | 1 | $105 |
| Bausch Health US, LLC | 1 | $102 |
| Akorn Operating Company LLC | 4 | $81 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $69 |
| Akorn, Inc. | 3 | $66 |
| Carl Zeiss Meditec USA, Inc. | 1 | $62 |
| Tarsus Pharmaceuticals, Inc. | 2 | $55 |
| Eyevance Pharmaceuticals LLC | 3 | $49 |
| Dompe US, Inc. | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Omeros Corporation | 1 | $20 |
| Thea Pharma Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$19,821
- RXSIGHT INJECTOR CARTRIDGE$19,821
- RXSIGHT INJECTOR HANDPIECE$19,821
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$19,821
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$19,366
- LENSAR LASER SYSTEM$7,748
- LIGHT ADJUSTABLE LENS (LAL)$455
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$362
- iDoseTR$308
- TEPEZZA$276
- Photrexa Viscous and Photrexa$265
- iStent Infinite$179
- iStent Trabecular Micro-Bypass Stent System$128
- iStent inject Trabecular Micro-Bypass Stent System$128
- Photrexa$128
- DURYSTA$112
- XIIDRA$110
How this compares
$32,316 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 16 | $14,880 |
| Prednisolone Acetate | 60 | $2,744 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,455 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 44 | $1,770 |
| Fluorometholone | 15 | $1,063 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $269 |
| Latanoprost | 16 | $150 |
| Tobramycin | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $444 | $14,88016 claims |
| AlconSimbrinza | $183 | $2,45512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$1.8M
- Gregory ParkhurstSan Antonio$185K
- James LehmannSan Antonio$162K
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.